转移性大肠癌免疫治疗的现状  

Current Status of Immunotherapy for Metastatic Colorectal Cancer

作　　者：刘兆辉[1] 张磊[1] 徐小平[1] 潘渊[1] 陈冬[1] 刘道成 陈敏[1] 徐栋[2] LIU Zhaohui;ZHANG Lei;XU Xiaoping;PAN Yuan;CHEN Dong;LIU Daocheng;CHEN Min;XU Dong(Department of Anorectal Surgery,The First People’s Hospital of Yuhang District,Hangzhou 311100,China;Department of Colorectal Surgery and Oncology,The Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 311100,China)

机构地区：[1]杭州市余杭区第一人民医院肛肠外科,杭州311100 [2]浙江大学医学院附属第二医院结直肠肿瘤外科,杭州311100

出　　处：《肿瘤防治研究》2020年第12期925-930,共6页Cancer Research on Prevention and Treatment

摘　　要：结直肠癌(CRC)是全世界常见恶性肿瘤之一,也是癌症患者死亡的主要原因,手术、放疗、化疗可以改善CRC患者预后,但晚期复发及远处转移疾病无法治愈,产生不良预后。随着分子生物学、肿瘤学以及免疫学的交叉渗透,免疫治疗取得巨大突破,已成为肿瘤治疗的一种重要手段。本文就近年来国内外转移性大肠癌免疫治疗情况作一综述。Colorectal cancer(CRC)is one of the most common malignant tumors in the world,which is also the main death cause of cancer patients.Surgery,radiotherapy and chemotherapy can improve the prognosis of CRC patients.However,late recurrence and distant metastatic diseases cannot be cured,which will result in poor prognosis.With the cross penetration of molecular biology,oncology and immunology,the immunotherapy has made a huge breakthrough and has become an important means of tumor therapy.This article summarizes the immunotherapy of metastatic CRC at home and abroad in recent years.

关 键 词：大肠癌 肿瘤转移 免疫治疗 

分 类 号：R735.3[医药卫生—肿瘤]